Research Networks

WIRE collaborates with institutions across the globe through formal research networks and consortia.

45+

Institutions

42

Cities

8

Countries

312+

Co-pubs

United States

Northwestern

Chicago, IL

46

MUSC

Charleston, SC

27

Ohio State

Columbus, OH

24

U of Colorado

Aurora, CO

23

Harvard / BCH

Boston, MA

18

Baylor / TCH

Houston, TX

13

Case Western

Cleveland, OH

11

U of Pittsburgh

Pittsburgh, PA

11

CHOP / Penn

Philadelphia, PA

10

U of Iowa

Iowa City, IA

10

Wash U

St. Louis, MO

10

Johns Hopkins

Baltimore, MD

10

Yale

New Haven, CT

7

U of Michigan

Ann Arbor, MI

7

UAB

Birmingham, AL

7
Canada

U of Calgary

Calgary, AB

40

SickKids

Toronto, ON

12

CHEO

Ottawa, ON

10

McGill

Montreal, QC

8
International

Sapienza

Rome, Italy

8

Showing top 20 of 45+ institutional partners across 42 cities in 8 countries

Networks & Consortia

The RESUME trial is a large, multicenter, randomized, comparative effectiveness study investigating the optimal timing for resuming direct oral anticoagulants (DOACs) after high-risk gastrointestinal endoscopy. The study aims to address a critical gap in evidence, balancing the risk of delayed GI bleeding with the risk of thromboembolic events, in a growing population of patients taking DOACs who require endoscopic procedures.

Main Purpose

Determine whether delaying DOAC resumption after high-risk endoscopy reduces clinically significant GI bleeding without a significant increase in thromboembolic risk.

Principal Investigator

Zachary Smith, DO, MSc

Funding

Pending

Network Sites

Medical College of Wisconsin (MCW)Atrium-Wake ForestNorthwestern UniversityBrigham and Women's Hospital / TIMI Study GroupUniversity of CalgaryUniversity of ColoradoMcGill UniversityUniversity of KansasUniversity of VirginiaDartmouth-HitchcockUniversity Hospitals of Cleveland

The Stents Versus Indomethacin (SVI) trial was a landmark, multicenter, randomized, double-blind, non-inferiority trial evaluating whether rectal indomethacin alone is as effective as the combination of rectal indomethacin plus prophylactic pancreatic stent placement for preventing pancreatitis after high-risk ERCP. The trial established that indomethacin alone was not as effective as the combined strategy, supporting current guideline recommendations to use both interventions in high-risk cases. The SVI Study Group continues to collaborate on impactful research, including post hoc SVI analyses and other impactful endoscopic research.

Main Purpose

To determine whether prophylactic pancreatic stent placement provides additional benefit over rectal indomethacin alone in preventing post-ERCP pancreatitis among high-risk patients.

Principal Investigator

B. Joseph Elmunzer, MD, MSc (Medical University of South Carolina)

Funding

National Institutes of Health (NIDDK), grant U01DK104833

Network Sites

Medical University of South CarolinaOregon Health & Science UniversityUniversity of Colorado Anschutz Medical CampusOrlando Health Digestive Health InstituteJohns Hopkins Medical InstitutionsUniversity of Michigan Medical CenterEmory University School of MedicineThe Ohio State University Wexner Medical CenterUniversity Hospitals Case Medical Center (Cleveland, OH)University of Pittsburgh Medical CenterWashington University School of Medicine (St. Louis, MO)University of Southern CaliforniaNorthwestern University Feinberg School of MedicineDartmouth-Hitchcock Medical CenterUniversity of Calgary (Canada)University of Kansas Medical CenterVirginia Mason Medical CenterVanderbilt University Medical CenterMcGill University (Canada)Medical College of WisconsinMayo Clinic (Rochester, MN)University of VirginiaBrigham and Women's Hospital

The Large Polyp Study Group is a collaborative research network conducting multiple high-impact studies on advanced endoscopic resection techniques for large colorectal polyps. Their hallmark work — a large, multicenter randomized controlled trial comparing cold snare EMR and hot EMR for large colon polyps — was ultimately published in Gut and is regarded as a major contribution to the field. The group continues to collaborate on innovative, practice-changing EMR research across diverse academic centers.

Main Purpose

To advance the safety, efficacy, and technique of endoscopic mucosal resection (EMR) for large colorectal polyps through multicenter, collaborative research.

Principal Investigator

Heiko Pohl, MD

Funding

Supported by research grants from STERIS and Cosmo Pharmaceuticals

Network Sites

Dartmouth-Hitchcock Medical Center (Lebanon, NH) / VA White River Junction, VTMedical College of Wisconsin (Milwaukee, WI)Indiana University School of MedicineSpectrum Health Butterworth Hospital (Grand Rapids, MI)Penn State Health Milton S. Hershey Medical CenterMedical University of South CarolinaUniversity of Kansas Medical CenterYale-New Haven HospitalHenry Ford Hospital (Detroit, MI)University of Montreal Medical Center (CHUM), CanadaMayo Clinic Jacksonville (Jacksonville, FL)Northwestern University Feinberg School of Medicine (Chicago, IL)New York University (NYU) Langone HealthBeth Israel Deaconess Medical Center (Boston, MA)Sanford Center for Digestive Health (Sioux Falls, SD)University of Nebraska Medical Center (Omaha, NE)AdventHealth Orlando

The CAN Resect Study Group is a collaborative research network uniting leading centers across the US and Canada to advance the safety and efficacy of endoscopic mucosal resection (EMR) for large colorectal polyps. The group conducts multicenter, randomized trials that address the most pressing clinical questions in polyp resection, including innovations in non-thermic techniques, prevention of recurrence, and the role of adjuvant therapies. Its studies are shaping guidelines and best practices for endoscopic management of large polyps.

Main Purpose

To compare innovative EMR techniques — such as non-thermic EMR and adjuvant thermal ablation — for large colorectal polyps, aiming to reduce recurrence and adverse events while improving cost-effectiveness and patient safety.

Principal Investigator

Daniel von Renteln, MD (CHUM, Montreal)

Funding

Supported by the Canadian Institutes of Health Research (CIHR)

Network Sites

Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QCMcGill University Health Centre, Montreal, QCSt. Michael's Hospital, Toronto, ONSt. Paul's Hospital, Vancouver, BCLondon Health Sciences Centre, London, ONForzani & MacPhail Colon Cancer Screening Centre, Calgary, ABMedical College of Wisconsin, Milwaukee, WI (US)Johns Hopkins Hospital, Baltimore, MD (US)White River Junction VA Hospital, White River Junction, VT (US)

The Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is a prospective, multi-center registry designed to capture detailed clinical, technical, and outcome data for ERCP procedures performed across leading Canadian centers. CReATE serves as a foundational data platform for high-impact studies on ERCP effectiveness, safety, risk factors for adverse events, and training outcomes, ultimately aiming to improve the quality and value of endoscopic care.

Main Purpose

To systematically collect and analyze data on ERCP procedures in order to better understand clinical effectiveness, patient outcomes, risk factors for adverse events, and the impact of educational practices in advanced endoscopy.

Principal Investigator

Nauzer Forbes, MD, MSc (University of Calgary)

Funding

Intramural

Network Sites

University of Calgary (Peter Lougheed Centre)University of Toronto (St. Michael's Hospital)McGill University (Montreal General Hospital and Royal Victoria Hospital)Medical College of Wisconsin